Previous 10 | Next 10 |
2024-03-08 10:21:57 ET More on Teva Pharmaceutical Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position A Review Of Teva's Prospects UroGen falls as Te...
2024-03-07 13:29:15 ET More on AstraZeneca, CSL, etc. Sanofi (SNY) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgr...
2024-03-06 16:13:40 ET Summary Apogee Therapeutics, Inc. positive interim results achieved from Phase 1 study of APG777 for Atopic Dermatitis and Phase 2 study initiation and additional data expected in 1st half of 2024 and 2025, respectively. Company has potential to overcom...
2024-03-05 13:28:08 ET Summary Apogee Therapeutics' APG777 shows promising Phase 1 results for AD, with a notably long half-life potentially reducing dosing frequency. APG777's efficacy and safety profiles justify Phase 2 trials, aiming to outperform competitors like Sanofi's Dupi...
2024-03-05 11:50:22 ET More on STOXX Europe 600 Index: Forex Becalmed With The Greenback Mostly Firmer In Narrow Ranges Narrowly Mixed Dollar To Start The Big Week For Europe And North America March 2024 Monthly European winners and losers of AI adoption - JP...
2024-02-25 20:48:41 ET Summary Exscientia's stock has been stagnant, with a 22% drop after the termination of its CEO due to inappropriate conduct. The company's pipeline efforts include CDK7 inhibitor GTAEXS617 and LSD1 inhibitor EXS74539, with clinical trials starting this year....
2024-02-23 05:40:38 ET Sanofi ( NASDAQ: SNY ) and partner Regeneron Pharmaceuticals ( NASDAQ: REGN ) announced Friday the receipt of priority review for their supplemental biologics license application (sBLA) for Dupixent (dupilumab), an anti-inflammatory medication.... ...
2024-02-22 21:01:24 ET Summary Novo Nordisk had a near perfect FY23. Fundamentally, FY24 should look quite similar. In reviewing FY23 results and commentary, we discuss key points like SELECT outcomes; CagriSema progress; and expansion into cardiovascular disease. Though expen...
2024-02-21 07:13:01 ET Regeneron ( NASDAQ: REGN ) and Vertex Pharmaceuticals ( NASDAQ: VRTX ) have crossed $100B in market capitalization for the first time, joining two other giants in the biotech industry, Amgen ( AMGN ) and AbbVie ( ABBV ).... Read the full ...
2024-02-20 10:28:47 ET More on Sanofi Sanofi (SNY) Q4 2023 Earnings Call Transcript Sanofi 2023 Q4 - Results - Earnings Call Presentation Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition Denali slips as Sanofi fails in mid-stage trial fo...
News, Short Squeeze, Breakout and More Instantly...
Sanofi ships U.S. influenza vaccines for the 2024/25 season PR Newswire Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
2024-07-09 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...